Hepaxane (Enoxaparin Sodium)

Hepaxane is prescribed to manage and prevent clot‑related conditions in various clinical settings. Its anticoagulant action is utilized according to established guidelines for patients at risk of venous thrombosis or requiring procedural anticoagulation.

• Prevention of deep vein thrombosis (DVT) in patients undergoing orthopedic surgery or prolonged immobilization.
• Treatment of acute DVT to reduce clot extension and recurrence.
• Prevention and treatment of pulmonary embolism (PE) in at‑risk populations.
• Anticoagulation during haemodialysis to maintain circuit patency.
• Peri‑operative anticoagulation when rapid onset and predictable effect are desired.

The safety profile of Hepaxane includes a range of observed adverse reactions, which are categorized by frequency and clinical significance.

Common

• Injection site bruising or pain.
• Minor gastrointestinal upset such as nausea.
• Transient increase in bleeding time, leading to easy bruising.
• Mild elevation of liver enzymes.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Severe thrombocytopenia (low platelet count) that may cause bleeding.
• Allergic reactions such as rash, itching, or anaphylaxis.
• Spinal or epidural hematoma following neuraxial procedures.

Before initiating Hepaxane therapy, clinicians should evaluate patient‑specific factors and monitor for conditions that could increase the risk of bleeding or other complications.

• Assess renal function; dose adjustment may be required in severe impairment.
• Review history of heparin‑induced thrombocytopenia (HIT) before use.
• Avoid use in patients with active major bleeding or uncontrolled hypertension.
• Monitor complete blood count and coagulation parameters regularly during treatment.
• Use caution in pregnancy; benefits and risks should be weighed individually.
• Discontinue before invasive procedures unless bridging anticoagulation is planned.

Hepaxane can interact with several medications, affecting anticoagulant intensity or increasing bleeding risk; some combinations should be avoided.

Avoid

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) unless specifically directed.
• Combination with antiplatelet agents such as aspirin, clopidogrel, or ticagrelor without close monitoring.
• Concomitant administration of fibrinolytic therapy (e.g., alteplase) due to heightened hemorrhagic risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may impair platelet function.
• Selective serotonin reuptake inhibitors (SSRIs) or other drugs that affect platelet aggregation.
• Certain antibiotics (e.g., vancomycin) that can potentiate anticoagulant effects.